{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:13:47Z","timestamp":1793146427351,"version":"4.5.0"},"reference-count":249,"publisher":"The Endocrine Society","issue":"6","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,12,1]]},"DOI":"10.1210\/er.2018-00139","type":"journal-article","created":{"date-parts":[[2018,8,15]],"date-time":"2018-08-15T14:03:47Z","timestamp":1534341827000},"page":"1057-1088","source":"Crossref","is-referenced-by-count":287,"title":["The Expanding Spectrum of Primary Aldosteronism: Implications for Diagnosis, Pathogenesis, and Treatment"],"prefix":"10.1210","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0314-9252","authenticated-orcid":false,"given":"Anand","family":"Vaidya","sequence":"first","affiliation":[{"name":"Center for Adrenal Disorders, Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Mulatero","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine and Hypertension, Department of Medical Sciences, University of Torino, Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene","family":"Baudrand","sequence":"additional","affiliation":[{"name":"Program for Adrenal Disorders and Hypertension, Department of Endocrinology, Pontificia Universidad Catolica de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail K","family":"Adler","sequence":"additional","affiliation":[{"name":"Center for Adrenal Disorders, Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2018,8,15]]},"reference":[{"key":"2019041122013772000_B1","volume-title":"On the Constitutional and Local Effects of Disease of the Supra-Renal Capsules","author":"Addison","year":"1855"},{"issue":"4","key":"2019041122013772000_B2","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1210\/endo-24-4-526","article-title":"Fractionation studies on adrenal cortical extract with notes on the distribution of biological activity among the crystalline and amorphous fractions","volume":"24","author":"Kuizenga","year":"1939","journal-title":"Endocrinology"},{"issue":"3","key":"2019041122013772000_B3","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1210\/endo-43-3-133","article-title":"The effect of altered sodium or potassium intake on the width and cytochemistry of the zona glomerulosa of the rat\u2019s adrenal cortex","volume":"43","author":"Deane","year":"1948","journal-title":"Endocrinology"},{"issue":"4306","key":"2019041122013772000_B4","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/169795a0","article-title":"Isolation of a highly active mineralocorticoid from beef adrenal extract","volume":"169","author":"Grundy","year":"1952","journal-title":"Nature"},{"issue":"6727","key":"2019041122013772000_B5","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0140-6736(52)91551-1","article-title":"Secretion of a salt-retaining hormone by the mammalian adrenal cortex","volume":"2","author":"Simpson","year":"1952","journal-title":"Lancet"},{"issue":"6","key":"2019041122013772000_B6","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1210\/jc.2003-030490","article-title":"50th Anniversary of aldosterone","volume":"88","author":"Williams","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2019041122013772000_B7","first-page":"3","article-title":"Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome","volume":"45","author":"Conn","year":"1955","journal-title":"J Lab Clin Med"},{"issue":"2","key":"2019041122013772000_B8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1001\/archinte.1956.00250200011001","article-title":"Aldosterone in clinical medicine; past, present, and future","volume":"97","author":"Conn","year":"1956","journal-title":"AMA Arch Intern Med"},{"issue":"3","key":"2019041122013772000_B9","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1001\/jama.1964.03070160046009","article-title":"Plasma renin activity in primary aldosteronism. Importance in differential diagnosis and in research of essential hypertension","volume":"190","author":"Conn","year":"1964","journal-title":"JAMA"},{"key":"2019041122013772000_B10","volume-title":"Aldosterone and Aldosteronism","author":"Ross","year":"1975"},{"issue":"2","key":"2019041122013772000_B11","doi-asserted-by":"crossref","first-page":"266","DOI":"10.7326\/0003-4819-63-2-266","article-title":"Normal and altered function of the renin-angiotensin-aldosterone system in man: applications in clinical and research medicine","volume":"63","author":"Conn","year":"1965","journal-title":"Ann Intern Med"},{"issue":"1","key":"2019041122013772000_B12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.7326\/0003-4819-72-1-9","article-title":"Suppressed plasma renin activity in essential hypertension. Roles of plasma volume, blood pressure, and sympathetic nervous system","volume":"72","author":"Jose","year":"1970","journal-title":"Ann Intern Med"},{"issue":"2","key":"2019041122013772000_B13","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/archinte.1969.00300120019003","article-title":"Suppressed plasma renin activity in hypertension","volume":"123","author":"Channick","year":"1969","journal-title":"Arch Intern Med"},{"issue":"9\u201310","key":"2019041122013772000_B14","first-page":"1869","article-title":"The salivary sodium\/potassium ratio in hypertension: relation to race and plasma renin activity","volume":"4","author":"Adlin","year":"1982","journal-title":"Clin Exp Hypertens A"},{"issue":"4","key":"2019041122013772000_B15","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1001\/archinte.1969.00300140012004","article-title":"Effect of an adrenal inhibitor in hypertensive patients with suppressed renin","volume":"123","author":"Woods","year":"1969","journal-title":"Arch Intern Med"},{"issue":"6","key":"2019041122013772000_B16","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1001\/archinte.1972.03650060047008","article-title":"Spironolactone and hydrochlorothiazide in essential hypertension. Blood pressure response and plasma renin activity","volume":"130","author":"Adlin","year":"1972","journal-title":"Arch Intern Med"},{"issue":"9","key":"2019041122013772000_B17","doi-asserted-by":"crossref","first-page":"673","DOI":"10.7326\/M17-2237","article-title":"Subclinical primary aldosteronism","volume":"167","author":"Adlin","year":"2017","journal-title":"Ann Intern Med"},{"issue":"6","key":"2019041122013772000_B18","doi-asserted-by":"crossref","first-page":"R249","DOI":"10.1530\/EJE-15-1118","article-title":"Endocrine tumours: the genomics of adrenocortical tumors","volume":"174","author":"Faillot","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2019041122013772000_B19","doi-asserted-by":"crossref","first-page":"R101","DOI":"10.1530\/EJE-17-0946","article-title":"Genetics in endocrinology: the expanding genetic horizon of primary aldosteronism","volume":"178","author":"Monticone","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2019041122013772000_B20","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1161\/HYPERTENSIONAHA.117.10111","article-title":"Old and new concepts in the molecular pathogenesis of primary aldosteronism","volume":"70","author":"Prada","year":"2017","journal-title":"Hypertension"},{"issue":"6","key":"2019041122013772000_B21","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1210\/er.2017-00189","article-title":"Genetic causes of functional adrenocortical adenomas","volume":"38","author":"Zennaro","year":"2017","journal-title":"Endocr Rev"},{"issue":"9","key":"2019041122013772000_B22","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S2213-8587(16)30113-9","article-title":"Adrenal vein sampling for subtyping in primary aldosteronism","volume":"4","author":"Reincke","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"2019041122013772000_B23","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1161\/HYPERTENSIONAHA.115.04930","article-title":"Adrenal venous sampling for differentiating unilateral from bilateral primary aldosteronism: still the best, but could be better","volume":"65","author":"Stowasser","year":"2015","journal-title":"Hypertension"},{"issue":"1","key":"2019041122013772000_B24","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1161\/HYPERTENSIONAHA.113.02097","article-title":"An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism","volume":"63","author":"Rossi","year":"2014","journal-title":"Hypertension"},{"issue":"3","key":"2019041122013772000_B25","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1161\/HYPERTENSIONAHA.116.08820","article-title":"Adrenal venous sampling versus computed tomographic scan to determine treatment in primary aldosteronism (the SPARTACUS trial): a critique","volume":"69","author":"Rossi","year":"2017","journal-title":"Hypertension"},{"issue":"4","key":"2019041122013772000_B26","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1152\/physrev.00026.2015","article-title":"Primary aldosteronism: changing definitions and new concepts of physiology and pathophysiology both inside and outside the kidney","volume":"96","author":"Stowasser","year":"2016","journal-title":"Physiol Rev"},{"issue":"5","key":"2019041122013772000_B27","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1210\/en.2010-1444","article-title":"Mineralocorticoid receptors: evolutionary and pathophysiological considerations","volume":"152","author":"Kassahn","year":"2011","journal-title":"Endocrinology"},{"issue":"5","key":"2019041122013772000_B28","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3390\/ijms18051032","article-title":"Aldosterone and mineralocorticoid receptors\u2014physiology and pathophysiology","volume":"18","author":"Funder","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2019041122013772000_B29","doi-asserted-by":"crossref","first-page":"T1","DOI":"10.1530\/JOE-16-0661","article-title":"30 Years of the mineralocorticoid receptor: evolution of the mineralocorticoid receptor: sequence, structure and function","volume":"234","author":"Baker","year":"2017","journal-title":"J Endocrinol"},{"issue":"3","key":"2019041122013772000_B30","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/MED.0000000000000152","article-title":"Cortisol dysregulation in obesity-related metabolic disorders","volume":"22","author":"Baudrand","year":"2015","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"4","key":"2019041122013772000_B31","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1525-142X.2006.00106.x","article-title":"Developmental plasticity and disparity in early dipnoan (lungfish) dentitions","volume":"8","author":"Ahlberg","year":"2006","journal-title":"Evol Dev"},{"issue":"1","key":"2019041122013772000_B32","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1152\/physrev.00011.2014","article-title":"Epithelial sodium transport and its control by aldosterone: the story of our internal environment revisited","volume":"95","author":"Rossier","year":"2015","journal-title":"Physiol Rev"},{"issue":"5","key":"2019041122013772000_B33","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/BF00302553","article-title":"The steroidogenic response to angiotensin II in the Australian lungfish, Neoceratodus forsteri","volume":"164","author":"Joss","year":"1994","journal-title":"J Comp Physiol"},{"key":"2019041122013772000_B34","unstructured":"Kronenberg H , MelmedS, PolonskyK, LarsenP. Williams Textbook of Endocrinology. 11th ed. Philadelphia, PA: Saunders; 2008."},{"issue":"6","key":"2019041122013772000_B35","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.2215\/CJN.08580813","article-title":"Regulation of potassium homeostasis","volume":"10","author":"Palmer","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"2019041122013772000_B36","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2215\/CJN.08880914","article-title":"Collecting duct intercalated cell function and regulation","volume":"10","author":"Roy","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"2019041122013772000_B37","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.cmet.2013.10.005","article-title":"Mineralocorticoid receptor phosphorylation regulates ligand binding and renal response to volume depletion and hyperkalemia","volume":"18","author":"Shibata","year":"2013","journal-title":"Cell Metab"},{"issue":"2","key":"2019041122013772000_B38","first-page":"115","article-title":"Aldosterone paradox: differential regulation of ion transport in distal nephron","volume":"26","author":"Arroyo","year":"2011","journal-title":"Physiology (Bethesda)"},{"issue":"3","key":"2019041122013772000_B39","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/ajcn\/47.3.502","article-title":"Responses of sodium balance, blood pressure, and other variables to sodium loading in Papua New Guinea highlanders","volume":"47","author":"Rikimaru","year":"1988","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"2019041122013772000_B40","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1161\/01.CIR.52.1.146","article-title":"Blood pressure, sodium intake, and sodium related hormones in the Yanomamo Indians, a \u201cno-salt\u201d culture","volume":"52","author":"Oliver","year":"1975","journal-title":"Circulation"},{"issue":"9","key":"2019041122013772000_B41","doi-asserted-by":"crossref","first-page":"630","DOI":"10.7326\/M17-0882","article-title":"The spectrum of subclinical primary aldosteronism and incident hypertension: a cohort study","volume":"167","author":"Brown","year":"2017","journal-title":"Ann Intern Med"},{"issue":"3","key":"2019041122013772000_B42","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1161\/01.HYP.14.3.238","article-title":"Blood pressure in four remote populations in the INTERSALT Study","volume":"14","author":"Carvalho","year":"1989","journal-title":"Hypertension"},{"issue":"1","key":"2019041122013772000_B43","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3945\/ajcn.116.139758","article-title":"Reproducibility of urinary biomarkers in multiple 24-h urine samples","volume":"105","author":"Sun","year":"2017","journal-title":"Am J Clin Nutr"},{"issue":"3","key":"2019041122013772000_B44","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1161\/HYPERTENSIONAHA.109.130492","article-title":"Independent relations of left ventricular structure with the 24-hour urinary excretion of sodium and aldosterone","volume":"54","author":"Jin","year":"2009","journal-title":"Hypertension"},{"issue":"1","key":"2019041122013772000_B45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3317\/jraas.2007.001","article-title":"Of snakes and men: the evolution of ACE inhibitors","volume":"8","author":"Bomback","year":"2007","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"8","key":"2019041122013772000_B46","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1096\/fj.03-0093life","article-title":"The discovery of captopril","volume":"17","author":"Smith","year":"2003","journal-title":"FASEB J"},{"issue":"10","key":"2019041122013772000_B47","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"issue":"10","key":"2019041122013772000_B48","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1210\/endo.141.10.7711","article-title":"Aldosterone: a mediator of myocardial necrosis and renal arteriopathy","volume":"141","author":"Rocha","year":"2000","journal-title":"Endocrinology"},{"issue":"2 Pt 2","key":"2019041122013772000_B49","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1161\/hyp.39.2.614","article-title":"Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading","volume":"39","author":"Martinez","year":"2002","journal-title":"Hypertension"},{"issue":"6","key":"2019041122013772000_B50","first-page":"893","article-title":"Mineralocorticoid excess, dietary sodium, and myocardial fibrosis","volume":"120","author":"Brilla","year":"1992","journal-title":"J Lab Clin Med"},{"key":"2019041122013772000_B51","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3389\/fphar.2017.00313","article-title":"Mineralocorticoid receptor signaling as a therapeutic target for renal and cardiac fibrosis","volume":"8","author":"Tesch","year":"2017","journal-title":"Front Pharmacol"},{"issue":"9","key":"2019041122013772000_B52","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/nm.2891","article-title":"Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors","volume":"18","author":"McCurley","year":"2012","journal-title":"Nat Med"},{"issue":"6","key":"2019041122013772000_B53","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1161\/HYPERTENSIONAHA.117.09598","article-title":"Endothelial mineralocorticoid receptor mediates parenchymal arteriole and posterior cerebral artery remodeling during angiotensin II\u2013induced hypertension","volume":"70","author":"Diaz-Otero","year":"2017","journal-title":"Hypertension"},{"issue":"5","key":"2019041122013772000_B54","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1161\/HYPERTENSIONAHA.115.06172","article-title":"Endothelial mineralocorticoid receptors differentially contribute to coronary and mesenteric vascular function without modulating blood pressure","volume":"66","author":"Mueller","year":"2015","journal-title":"Hypertension"},{"issue":"12","key":"2019041122013772000_B55","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/1440-1681.12125","article-title":"Direct contribution of vascular mineralocorticoid receptors to blood pressure regulation","volume":"40","author":"Barrett","year":"2013","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"4","key":"2019041122013772000_B56","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1161\/HYPERTENSIONAHA.117.10437","article-title":"Smooth muscle cell\u2013mineralocorticoid receptor as a mediator of cardiovascular stiffness with aging","volume":"71","author":"Kim","year":"2018","journal-title":"Hypertension"},{"issue":"4","key":"2019041122013772000_B57","first-page":"419","article-title":"Increase in plasma ouabainlike inhibitor of Na+, K+-ATPase with high sodium intake in patients with essential hypertension","volume":"3","author":"Hasegawa","year":"1987","journal-title":"J Clin Hypertens"},{"issue":"1","key":"2019041122013772000_B58","doi-asserted-by":"crossref","first-page":"H273","DOI":"10.1152\/ajpheart.00183.2008","article-title":"ACTH-induced hypertension is dependent on the ouabain-binding site of the \u03b12-Na+-K+-ATPase subunit","volume":"295","author":"Lorenz","year":"2008","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1 Pt 2","key":"2019041122013772000_B59","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1161\/01.HYP.29.1.401","article-title":"Angiotensin II stimulates secretion of endogenous ouabain from bovine adrenocortical cells via angiotensin type 2 receptors","volume":"29","author":"Laredo","year":"1997","journal-title":"Hypertension"},{"issue":"3","key":"2019041122013772000_B60","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1161\/HYPERTENSIONAHA.116.06599","article-title":"Endogenous ouabain: recent advances and controversies","volume":"68","author":"Hamlyn","year":"2016","journal-title":"Hypertension"},{"issue":"4","key":"2019041122013772000_B61","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1161\/HYPERTENSIONAHA.114.03919","article-title":"Endogenous ouabain is not ouabain","volume":"64","author":"Lewis","year":"2014","journal-title":"Hypertension"},{"key":"2019041122013772000_B62","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cca.2014.01.038","article-title":"No endogenous ouabain is detectable in human plasma by ultra-sensitive UPLC-MS\/MS","volume":"431","author":"Baecher","year":"2014","journal-title":"Clin Chim Acta"},{"issue":"5","key":"2019041122013772000_B63","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1161\/01.HYP.23.5.632","article-title":"Is ouabain an authentic endogenous mammalian substance derived from the adrenal","volume":"23","author":"Doris","year":"1994","journal-title":"Hypertension"},{"issue":"1","key":"2019041122013772000_B64","doi-asserted-by":"crossref","first-page":"I102","DOI":"10.1161\/01.HYP.23.1_Suppl.I102","article-title":"Does plasma immunoreactive ouabain originate from the adrenal gland","volume":"23","author":"Naruse","year":"1994","journal-title":"Hypertension"},{"key":"2019041122013772000_B65","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3389\/fendo.2016.00072","article-title":"Role of ACTH and other hormones in the regulation of aldosterone production in primary aldosteronism","volume":"7","author":"El Ghorayeb","year":"2016","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"2019041122013772000_B66","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1210\/jc.2015-1268","article-title":"Stress-induced aldosterone hyper-secretion in a substantial subset of patients with essential hypertension","volume":"100","author":"Markou","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2019041122013772000_B67","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1055\/s-0043-119802","article-title":"Primary aldosteronism: the next five years","volume":"49","author":"Funder","year":"2017","journal-title":"Horm Metab Res"},{"issue":"9","key":"2019041122013772000_B68","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1055\/s-0043-115226","article-title":"Aldosterone hypothesis for cognitive impairment in diabetes mellitus","volume":"49","author":"Saha","year":"2017","journal-title":"Horm Metab Res"},{"key":"2019041122013772000_B69","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.steroids.2014.08.014","article-title":"Brain mineralocorticoid receptors in cognition and cardiovascular homeostasis","volume":"91","author":"Gomez-Sanchez","year":"2014","journal-title":"Steroids"},{"issue":"4","key":"2019041122013772000_B70","first-page":"641","article-title":"[Brain renin-angiotensin-aldosterone system and cognitive function]","volume":"72","author":"Horiuchi","year":"2014","journal-title":"Nihon Rinsho"},{"issue":"4","key":"2019041122013772000_B71","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s12576-018-0612-x","article-title":"Obesity and episodic memory function","volume":"68","author":"Loprinzi","year":"2018","journal-title":"J Physiol Sci"},{"key":"2019041122013772000_B72","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.yfrne.2018.02.003","article-title":"Importance of the brain corticosteroid receptor balance in metaplasticity, cognitive performance and neuro-inflammation","volume":"49","author":"de Kloet","year":"2018","journal-title":"Front Neuroendocrinol"},{"issue":"6","key":"2019041122013772000_B73","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/oby.21104","article-title":"Effect of mineralocorticoid receptor blockade on hippocampal-dependent memory in adults with obesity","volume":"23","author":"Rotenstein","year":"2015","journal-title":"Obesity (Silver Spring)"},{"issue":"14","key":"2019041122013772000_B74","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/j.jacc.2017.01.052","article-title":"Prevalence and clinical manifestations of primary aldosteronism encountered in primary\u00a0care\u00a0practice","volume":"69","author":"Monticone","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2019041122013772000_B75","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1097\/HJH.0000000000001251","article-title":"Plasma aldosterone level within the normal range is less associated with cardiovascular and cerebrovascular risk in primary aldosteronism","volume":"35","author":"Murata","year":"2017","journal-title":"J Hypertens"},{"issue":"1","key":"2019041122013772000_B76","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/archinternmed.2007.33","article-title":"Cardiovascular outcomes in patients with primary aldosteronism after treatment","volume":"168","author":"Catena","year":"2008","journal-title":"Arch Intern Med"},{"issue":"8","key":"2019041122013772000_B77","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","article-title":"Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism","volume":"45","author":"Milliez","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"2019041122013772000_B78","doi-asserted-by":"crossref","first-page":"4826","DOI":"10.1210\/jc.2013-2805","article-title":"Long-term cardio- and cerebrovascular events in patients with primary aldosteronism","volume":"98","author":"Mulatero","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2019041122013772000_B79","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/BF03347840","article-title":"Vascular complications in patients with aldosterone producing adenoma in Japan: comparative study with essential hypertension","volume":"18","author":"Takeda","year":"1995","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"2019041122013772000_B80","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1161\/HYPERTENSIONAHA.112.197111","article-title":"Observational study mortality in treated primary aldosteronism: the German Conn\u2019s registry","volume":"60","author":"Reincke","year":"2012","journal-title":"Hypertension"},{"issue":"2","key":"2019041122013772000_B81","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1161\/HYPERTENSIONAHA.113.01060","article-title":"Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study","volume":"62","author":"Savard","year":"2013","journal-title":"Hypertension"},{"issue":"1","key":"2019041122013772000_B82","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","article-title":"Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study","volume":"6","author":"Hundemer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2019041122013772000_B83","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1161\/HYPERTENSIONAHA.113.01316","article-title":"Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism","volume":"62","author":"Rossi","year":"2013","journal-title":"Hypertension"},{"issue":"4","key":"2019041122013772000_B84","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/HYPERTENSIONAHA.117.10596","article-title":"Adrenalectomy lowers incident atrial fibrillation in primary aldosteronism patients at long term","volume":"71","author":"Rossi","year":"2018","journal-title":"Hypertension"},{"issue":"2","key":"2019041122013772000_B85","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1210\/jc.2005-1733","article-title":"Prevalence and characteristics of the metabolic syndrome in primary aldosteronism","volume":"91","author":"Fallo","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2019041122013772000_B86","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s11845-013-1007-x","article-title":"Elevated prevalence of abnormal glucose metabolism in patients with primary aldosteronism: a meta-analysis","volume":"183","author":"Chen","year":"2014","journal-title":"Ir J Med Sci"},{"issue":"5","key":"2019041122013772000_B87","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1530\/EJE-15-0450","article-title":"Increased prevalence of diabetes mellitus and the metabolic syndrome in patients with primary aldosteronism of the German Conn\u2019s Registry","volume":"173","author":"Hanslik","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2019041122013772000_B88","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.0000230444.01215.6a","article-title":"Renal damage in primary aldosteronism: results of the PAPY Study","volume":"48","author":"Rossi","year":"2006","journal-title":"Hypertension"},{"issue":"3","key":"2019041122013772000_B89","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1210\/jc.2008-1851","article-title":"Risk factors associated with a low glomerular filtration rate in primary aldosteronism","volume":"94","author":"Reincke","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2019041122013772000_B90","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1210\/jc.2016-3867","article-title":"Renin phenotypes characterize vascular disease, autonomous aldosteronism, and mineralocorticoid receptor activity","volume":"102","author":"Hundemer","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"22","key":"2019041122013772000_B91","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1001\/jama.295.22.2638","article-title":"Long-term renal outcomes in patients with primary aldosteronism","volume":"295","author":"Sechi","year":"2006","journal-title":"JAMA"},{"issue":"10","key":"2019041122013772000_B92","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1002\/jbmr.1660","article-title":"Bone involvement in aldosteronism","volume":"27","author":"Salcuni","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2019041122013772000_B93","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1530\/EJE-17-0417","article-title":"Primary aldosteronism as a cause of secondary osteoporosis","volume":"177","author":"Salcuni","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"2019041122013772000_B94","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1007\/s00198-013-2399-1","article-title":"Bone health and aldosterone excess","volume":"24","author":"Ceccoli","year":"2013","journal-title":"Osteoporos Int"},{"issue":"4","key":"2019041122013772000_B95","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/jbmr.3033","article-title":"Risk of fracture in primary aldosteronism: a population-based cohort study","volume":"32","author":"Wu","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2019041122013772000_B96","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2019041122013772000_B97","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2019041122013772000_B98","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0889-8529(02)00013-0","article-title":"Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature","volume":"31","author":"Montori","year":"2002","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"1","key":"2019041122013772000_B99","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1530\/EJE-11-1013","article-title":"Screening for primary aldosteronism in hypertensive subjects: results from two German epidemiological studies","volume":"167","author":"Hannemann","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"2019041122013772000_B100","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1001\/archinte.1981.00340130033011","article-title":"A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients","volume":"141","author":"Hiramatsu","year":"1981","journal-title":"Arch Intern Med"},{"issue":"5","key":"2019041122013772000_B101","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1210\/jcem-73-5-952","article-title":"Diagnosis under random conditions of all disorders of the renin-angiotensin-aldosterone axis, including primary hyperaldosteronism","volume":"73","author":"McKenna","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2019041122013772000_B102","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2265.2007.02775.x","article-title":"Primary aldosteronism: renaissance of a syndrome","volume":"66","author":"Young","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"2019041122013772000_B103","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/jch.12523","article-title":"Unadjusted plasma renin activity as a \u201cfirst-look\u201d test to decide upon further investigations for primary aldosteronism","volume":"17","author":"Rye","year":"2015","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"11","key":"2019041122013772000_B104","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1210\/jc.2016-1963","article-title":"Dietary sodium restriction increases the risk of misinterpreting mild cases of primary aldosteronism","volume":"101","author":"Baudrand","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2019041122013772000_B105","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1055\/s-0031-1295460","article-title":"Factors affecting the aldosterone\/renin ratio","volume":"44","author":"Stowasser","year":"2012","journal-title":"Horm Metab Res"},{"issue":"2","key":"2019041122013772000_B106","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1161\/01.HYP.0000079505.25750.11","article-title":"Primary aldosteronism and hypertensive disease","volume":"42","author":"Mosso","year":"2003","journal-title":"Hypertension"},{"issue":"6","key":"2019041122013772000_B107","doi-asserted-by":"crossref","first-page":"680","DOI":"10.4158\/EP161717.RA","article-title":"An individualized approach to the evaluation and management of primary aldosteronism","volume":"23","author":"Vaidya","year":"2017","journal-title":"Endocr Pract"},{"issue":"11","key":"2019041122013772000_B108","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.jacc.2006.07.059","article-title":"A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients","volume":"48","author":"Rossi","year":"2006","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2019041122013772000_B109","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1291\/hypres.27.193","article-title":"Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan","volume":"27","author":"Omura","year":"2004","journal-title":"Hypertens Res"},{"issue":"2","key":"2019041122013772000_B110","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/sj.jhh.1001948","article-title":"Prevalence of primary hyperaldosteronism in mild to moderate hypertension without hypokalaemia","volume":"20","author":"Williams","year":"2006","journal-title":"J Hum Hypertens"},{"issue":"10 Pt 1","key":"2019041122013772000_B111","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0895-7061(02)02969-2","article-title":"High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives","volume":"15","author":"Rossi","year":"2002","journal-title":"Am J Hypertens"},{"issue":"5","key":"2019041122013772000_B112","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/sj.jhh.1001554","article-title":"Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region","volume":"17","author":"\u0160trauch","year":"2003","journal-title":"J Hum Hypertens"},{"issue":"6","key":"2019041122013772000_B113","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1161\/01.HYP.0000040261.30455.B6","article-title":"Hyperaldosteronism among black and white subjects with resistant hypertension","volume":"40","author":"Calhoun","year":"2002","journal-title":"Hypertension"},{"issue":"3","key":"2019041122013772000_B114","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1161\/01.HYP.0000116223.97436.e5","article-title":"Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy","volume":"43","author":"Goodfriend","year":"2004","journal-title":"Hypertension"},{"issue":"1","key":"2019041122013772000_B115","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1378\/chest.125.1.112","article-title":"Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea","volume":"125","author":"Calhoun","year":"2004","journal-title":"Chest"},{"issue":"3","key":"2019041122013772000_B116","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11906-018-0819-5","article-title":"Role of mineralocorticoid receptors in obstructive sleep apnea and metabolic syndrome","volume":"20","author":"Valaiyapathi","year":"2018","journal-title":"Curr Hypertens Rep"},{"issue":"10008","key":"2019041122013772000_B117","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"2019041122013772000_B118","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S2213-8587(18)30071-8","article-title":"Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies","volume":"6","author":"Williams","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2019041122013772000_B119","doi-asserted-by":"crossref","first-page":"E546","DOI":"10.3390\/ijms19020546","article-title":"The low-renin hypertension phenotype: genetics and the role of the mineralocorticoid receptor","volume":"19","author":"Baudrand","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2019041122013772000_B120","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10157-010-0298-8","article-title":"Activation of the aldosterone\/mineralocorticoid receptor system in chronic kidney disease and metabolic syndrome","volume":"14","author":"Nagase","year":"2010","journal-title":"Clin Exp Nephrol"},{"issue":"2","key":"2019041122013772000_B121","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/nrneph.2012.282","article-title":"Role of Rac1\u2013mineralocorticoid-receptor signalling in renal and cardiac disease","volume":"9","author":"Nagase","year":"2013","journal-title":"Nat Rev Nephrol"},{"issue":"8","key":"2019041122013772000_B122","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1172\/JCI105437","article-title":"Distribution, conjugation, and excretion of labeled aldosterone in congestive heart failure and in controls with normal circulation: development and testing of a model with an analog computer","volume":"45","author":"Cheville","year":"1966","journal-title":"J Clin Invest"},{"issue":"4","key":"2019041122013772000_B123","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1210\/jc.2012-3353","article-title":"Evidence of primary aldosteronism in a predominantly female cohort of normotensive individuals: a very high odds ratio for progression into arterial hypertension","volume":"98","author":"Markou","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2019041122013772000_B124","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1161\/HYPERTENSIONAHA.116.08952","article-title":"Continuum of renin-independent aldosteronism in normotension","volume":"69","author":"Baudrand","year":"2017","journal-title":"Hypertension"},{"issue":"6","key":"2019041122013772000_B125","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1055\/s-0029-1246186","article-title":"Confirmatory tests in the diagnosis of primary aldosteronism","volume":"42","author":"Mulatero","year":"2010","journal-title":"Horm Metab Res"},{"issue":"7","key":"2019041122013772000_B126","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1210\/jc.2006-0078","article-title":"Comparison of confirmatory tests for the diagnosis of primary aldosteronism","volume":"91","author":"Mulatero","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041122013772000_B127","doi-asserted-by":"crossref","unstructured":"Monticone S , LosanoI, TettiM, BuffoloF, VeglioF, MulateroP. Diagnostic approach to low-renin hypertension. Clin Endocrinol (Oxf). 2018.","DOI":"10.1111\/cen.13741"},{"issue":"6","key":"2019041122013772000_B128","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/archinte.1972.03650060041007","article-title":"The syndrome of essential hypertension and suppressed plasma renin activity. Normalization of blood pressure with spironolactone","volume":"130","author":"Carey","year":"1972","journal-title":"Arch Intern Med"},{"issue":"7908","key":"2019041122013772000_B129","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0140-6736(75)91814-0","article-title":"Letter: plasma-renin and blood-pressure","volume":"1","author":"Adlin","year":"1975","journal-title":"Lancet"},{"issue":"4","key":"2019041122013772000_B130","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1161\/HYPERTENSIONAHA.111.00662","article-title":"Abnormal aldosterone physiology and cardiometabolic risk factors","volume":"61","author":"Vaidya","year":"2013","journal-title":"Hypertension"},{"issue":"6","key":"2019041122013772000_B131","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1161\/HYPERTENSIONAHA.114.03231","article-title":"Aldosterone dysregulation with aging predicts renal vascular function and cardiovascular risk","volume":"63","author":"Brown","year":"2014","journal-title":"Hypertension"},{"issue":"11","key":"2019041122013772000_B132","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1210\/jc.2007-1088","article-title":"Body mass index predicts aldosterone production in normotensive adults on a high-salt diet","volume":"92","author":"Bentley-Lewis","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2019041122013772000_B133","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1161\/CIRCULATIONAHA.117.028201","article-title":"Age-related autonomous aldosteronism","volume":"136","author":"Nanba","year":"2017","journal-title":"Circulation"},{"issue":"1","key":"2019041122013772000_B134","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa033263","article-title":"Serum aldosterone and the incidence of hypertension in nonhypertensive persons","volume":"351","author":"Vasan","year":"2004","journal-title":"N Engl J Med"},{"issue":"4","key":"2019041122013772000_B135","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1161\/01.HYP.0000258554.87444.91","article-title":"Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample","volume":"49","author":"Newton-Cheh","year":"2007","journal-title":"Hypertension"},{"issue":"2","key":"2019041122013772000_B136","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1210\/er.2017-00054","article-title":"Screening for endocrine hypertension: an Endocrine Society scientific statement","volume":"38","author":"Young","year":"2017","journal-title":"Endocr Rev"},{"issue":"10","key":"2019041122013772000_B137","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jash.2016.08.006","article-title":"Worldwide prevalence of hypertension exceeds 1.3 billion","volume":"10","author":"Bloch","year":"2016","journal-title":"J Am Soc Hypertens"},{"issue":"6","key":"2019041122013772000_B138","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.115.018912","article-title":"Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries","volume":"134","author":"Mills","year":"2016","journal-title":"Circulation"},{"issue":"14","key":"2019041122013772000_B139","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/j.jacc.2017.02.041","article-title":"The time has come for systematic screening for primary aldosteronism in\u00a0all\u00a0hypertensives","volume":"69","author":"Maiolino","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2019041122013772000_B140","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1210\/jcem-40-2-205","article-title":"Integrated concentration of plasma aldosterone in normal subjects: correlation with cortisol","volume":"40","author":"Kowarski","year":"1975","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2019041122013772000_B141","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1161\/HYPERTENSIONAHA.116.07214","article-title":"Suppression of aldosterone secretion after recumbent saline infusion does not exclude lateralized primary aldosteronism","volume":"68","author":"Cornu","year":"2016","journal-title":"Hypertension"},{"issue":"2","key":"2019041122013772000_B142","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1681\/ASN.2014111137","article-title":"Activation of the endogenous renin-angiotensin-aldosterone system or aldosterone administration increases urinary exosomal sodium channel excretion","volume":"27","author":"Qi","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"2019041122013772000_B143","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1681\/ASN.2015111221","article-title":"In primary aldosteronism, mineralocorticoids influence exosomal sodium-chloride cotransporter abundance","volume":"28","author":"Wolley","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"2019041122013772000_B144","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/HJH.0000000000001168","article-title":"Increased urinary excretion of the epithelial Na channel activator prostasin in patients with primary aldosteronism","volume":"35","author":"Pizzolo","year":"2017","journal-title":"J Hypertens"},{"issue":"8","key":"2019041122013772000_B145","doi-asserted-by":"crossref","first-page":"e93136","DOI":"10.1172\/jci.insight.93136","article-title":"Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism","volume":"2","author":"Arlt","year":"2017","journal-title":"JCI Insight"},{"issue":"1","key":"2019041122013772000_B146","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1161\/HYPERTENSIONAHA.115.06186","article-title":"Genotype-specific steroid profiles associated with aldosterone-producing adenomas","volume":"67","author":"Williams","year":"2016","journal-title":"Hypertension"},{"issue":"5","key":"2019041122013772000_B147","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1161\/HYPERTENSIONAHA.111.175083","article-title":"Prevalence and characteristics of familial hyperaldosteronism: the PATOGEN study (primary aldosteronism in torino-genetic forms)","volume":"58","author":"Mulatero","year":"2011","journal-title":"Hypertension"},{"issue":"6357","key":"2019041122013772000_B148","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/355262a0","article-title":"A chimaeric 11\u03b2-hydroxylase\/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension","volume":"355","author":"Lifton","year":"1992","journal-title":"Nature"},{"issue":"1","key":"2019041122013772000_B149","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1161\/HYPERTENSIONAHA.111.180513","article-title":"A new presentation of the chimeric CYP11B1\/CYP11B2 gene with low prevalence of primary aldosteronism and atypical gene segregation pattern","volume":"59","author":"Carvajal","year":"2012","journal-title":"Hypertension"},{"issue":"11","key":"2019041122013772000_B150","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/jmg.37.11.831","article-title":"A novel genetic locus for low renin hypertension: familial hyperaldosteronism type II maps to chromosome 7 (7p22)","volume":"37","author":"Lafferty","year":"2000","journal-title":"J Med Genet"},{"issue":"9","key":"2019041122013772000_B151","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/00004872-200018090-00002","article-title":"Primary aldosteronism: learning from the study of familial varieties","volume":"18","author":"Stowasser","year":"2000","journal-title":"J Hypertens"},{"issue":"8","key":"2019041122013772000_B152","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1210\/jc.2008-0594","article-title":"A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism","volume":"93","author":"Geller","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"6018","key":"2019041122013772000_B153","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1126\/science.1198785","article-title":"K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension","volume":"331","author":"Choi","year":"2011","journal-title":"Science"},{"issue":"2","key":"2019041122013772000_B154","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.mce.2011.07.034","article-title":"Acute and chronic regulation of aldosterone production","volume":"350","author":"Hattangady","year":"2012","journal-title":"Mol Cell Endocrinol"},{"issue":"4","key":"2019041122013772000_B155","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1210\/en.2011-1733","article-title":"Potassium channel mutant KCNJ5 T158A expression in HAC-15 cells increases aldosterone synthesis","volume":"153","author":"Oki","year":"2012","journal-title":"Endocrinology"},{"key":"2019041122013772000_B156","doi-asserted-by":"crossref","first-page":"e06315","DOI":"10.7554\/eLife.06315","article-title":"Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism","volume":"4","author":"Scholl","year":"2015","journal-title":"eLife"},{"issue":"13","key":"2019041122013772000_B157","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1055\/s-0035-1564166","article-title":"An update on familial hyperaldosteronism","volume":"47","author":"Korah","year":"2015","journal-title":"Horm Metab Res"},{"key":"2019041122013772000_B158","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ebiom.2016.10.002","article-title":"CACNA1H mutations are associated with different forms of primary aldosteronism","volume":"13","author":"Daniil","year":"2016","journal-title":"EBioMedicine"},{"issue":"4","key":"2019041122013772000_B159","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1113\/jphysiol.2013.264176","article-title":"Mechanisms by which a CACNA1H mutation in epilepsy patients increases seizure susceptibility","volume":"592","author":"Eckle","year":"2014","journal-title":"J Physiol"},{"issue":"31","key":"2019041122013772000_B160","doi-asserted-by":"crossref","first-page":"22085","DOI":"10.1074\/jbc.M603316200","article-title":"CACNA1H mutations in autism spectrum disorders","volume":"281","author":"Splawski","year":"2006","journal-title":"J Biol Chem"},{"issue":"9","key":"2019041122013772000_B161","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/ng.2695","article-title":"Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism","volume":"45","author":"Scholl","year":"2013","journal-title":"Nat Genet"},{"issue":"15","key":"2019041122013772000_B162","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1093\/hmg\/ddx175","article-title":"New gain-of-function mutation shows CACNA1D as recurrently mutated gene in autism spectrum disorders and epilepsy","volume":"26","author":"Pinggera","year":"2017","journal-title":"Hum Mol Genet"},{"issue":"9","key":"2019041122013772000_B163","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.biopsych.2014.11.020","article-title":"CACNA1D de novo mutations in autism spectrum disorders activate Cav1.3 L-type calcium channels","volume":"77","author":"Pinggera","year":"2015","journal-title":"Biol Psychiatry"},{"issue":"3","key":"2019041122013772000_B164","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41588-018-0053-8","article-title":"A gain-of-function mutation in the CLCN2 chloride channel gene causes primary aldosteronism","volume":"50","author":"Fernandes-Rosa","year":"2018","journal-title":"Nat Genet"},{"issue":"3","key":"2019041122013772000_B165","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41588-018-0048-5","article-title":"CLCN2 chloride channel mutations in familial hyperaldosteronism type II","volume":"50","author":"Scholl","year":"2018","journal-title":"Nat Genet"},{"issue":"10","key":"2019041122013772000_B166","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1210\/jc.2018-01004","article-title":"Targeted molecular characterization of aldosterone-producing adenomas in white americans","volume":"103","author":"Nanba","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"2019041122013772000_B167","doi-asserted-by":"crossref","first-page":"E1089","DOI":"10.1210\/jc.2015-2149","article-title":"A meta-analysis of somatic KCNJ5 K+ channel mutations in 1636 patients with an aldosterone-producing adenoma","volume":"100","author":"Lenzini","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2019041122013772000_B168","doi-asserted-by":"crossref","first-page":"e41926","DOI":"10.1371\/journal.pone.0041926","article-title":"Comprehensive re-sequencing of adrenal aldosterone producing lesions reveal three somatic mutations near the KCNJ5 potassium channel selectivity filter","volume":"7","author":"\u00c5kerstr\u00f6m","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"2019041122013772000_B169","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1210\/jc.2015-3284","article-title":"Clinical and steroidogenic characteristics of aldosterone-producing adenomas with ATPase or CACNA1D gene mutations","volume":"101","author":"Kitamoto","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2019041122013772000_B170","doi-asserted-by":"crossref","first-page":"11396","DOI":"10.1038\/srep11396","article-title":"Prevalence and clinical correlates of somatic mutation in aldosterone producing adenoma-Taiwanese population","volume":"5","author":"Wu","year":"2015","journal-title":"Sci Rep"},{"issue":"16","key":"2019041122013772000_B171","doi-asserted-by":"crossref","first-page":"e708","DOI":"10.1097\/MD.0000000000000708","article-title":"Prevalence and characterization of somatic mutations in Chinese aldosterone-producing adenoma patients","volume":"94","author":"Wang","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"2019041122013772000_B172","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1161\/HYPERTENSIONAHA.114.03346","article-title":"Clinical characteristics of somatic mutations in Chinese patients with aldosterone-producing adenoma","volume":"65","author":"Zheng","year":"2015","journal-title":"Hypertension"},{"issue":"2","key":"2019041122013772000_B173","doi-asserted-by":"crossref","first-page":"191","DOI":"10.5551\/jat.24455","article-title":"Comparison of cardiovascular complications in patients with and without KCNJ5 gene mutations harboring aldosterone-producing adenomas","volume":"22","author":"Kitamoto","year":"2015","journal-title":"J Atheroscler Thromb"},{"issue":"4","key":"2019041122013772000_B174","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1210\/jc.2011-2885","article-title":"Expression and mutations of KCNJ5 mRNA in Japanese patients with aldosterone-producing adenomas","volume":"97","author":"Taguchi","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2019041122013772000_B175","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/HYPERTENSIONAHA.114.03419","article-title":"Genetic spectrum and clinical correlates of somatic mutations in aldosterone-producing adenoma","volume":"64","author":"Fernandes-Rosa","year":"2014","journal-title":"Hypertension"},{"issue":"7","key":"2019041122013772000_B176","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1097\/HJH.0000000000001735","article-title":"Criteria for diagnosing primary aldosteronism on the basis of liquid chromatography\u2013tandem mass spectrometry determinations of plasma aldosterone concentration","volume":"36","author":"Baron","year":"2018","journal-title":"J Hypertens"},{"issue":"7","key":"2019041122013772000_B177","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1172\/JCI91733","article-title":"Macrolides selectively inhibit mutant KCNJ5 potassium channels that cause aldosterone-producing adenoma","volume":"127","author":"Scholl","year":"2017","journal-title":"J Clin Invest"},{"issue":"7","key":"2019041122013772000_B178","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1097\/HJH.0000000000000186","article-title":"KCNJ5 gene somatic mutations affect cardiac remodelling but do not preclude cure of high blood pressure and regression of left ventricular hypertrophy in primary aldosteronism","volume":"32","author":"Rossi","year":"2014","journal-title":"J Hypertens"},{"issue":"4","key":"2019041122013772000_B179","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/ans.12470","article-title":"Mutations in KCNJ5 determines presentation and likelihood of cure in primary hyperaldosteronism","volume":"85","author":"Ip","year":"2015","journal-title":"ANZ J Surg"},{"issue":"6","key":"2019041122013772000_B180","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s00423-013-1093-2","article-title":"Outcome after surgery for primary hyperaldosteronism may depend on KCNJ5 tumor mutation status: a population-based study from Western Norway","volume":"398","author":"Arnesen","year":"2013","journal-title":"Langenbecks Arch Surg"},{"issue":"1","key":"2019041122013772000_B181","doi-asserted-by":"crossref","first-page":"24697","DOI":"10.1038\/srep24697","article-title":"Regulation of aldosterone secretion by Cav1.3","volume":"6","author":"Xie","year":"2016","journal-title":"Sci Rep"},{"issue":"1","key":"2019041122013772000_B182","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/ncomms2149","article-title":"CaV1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson\u2019s disease","volume":"3","author":"Kang","year":"2012","journal-title":"Nat Commun"},{"issue":"4","key":"2019041122013772000_B183","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/ng.2550","article-title":"Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension","volume":"45","author":"Beuschlein","year":"2013","journal-title":"Nat Genet."},{"issue":"12","key":"2019041122013772000_B184","doi-asserted-by":"crossref","first-page":"4582","DOI":"10.1210\/en.2015-1466","article-title":"Pathogenesis of adrenal aldosterone-producing adenomas carrying mutations of the Na+\/K+-ATPase","volume":"156","author":"Stindl","year":"2015","journal-title":"Endocrinology"},{"issue":"1","key":"2019041122013772000_B185","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1161\/HYPERTENSIONAHA.113.01733","article-title":"Somatic ATP1A1, ATP2B3, and KCNJ5 mutations in aldosterone-producing adenomas","volume":"63","author":"Williams","year":"2014","journal-title":"Hypertension"},{"issue":"9","key":"2019041122013772000_B186","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/ng.2716","article-title":"Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension","volume":"45","author":"Azizan","year":"2013","journal-title":"Nat Genet"},{"issue":"7","key":"2019041122013772000_B187","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1073\/pnas.1121407109","article-title":"Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5","volume":"109","author":"Scholl","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"2019041122013772000_B188","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1161\/HYPERTENSIONAHA.118.11086","article-title":"Cellular and genetic causes of idiopathic hyperaldosteronism","volume":"72","author":"Omata","year":"2018","journal-title":"Hypertension."},{"issue":"10","key":"2019041122013772000_B189","doi-asserted-by":"crossref","first-page":"e008281","DOI":"10.1161\/JAHA.117.008281","article-title":"Epigenetic regulation of aldosterone synthase gene by sodium and angiotensin II","volume":"7","author":"Takeda","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"2019041122013772000_B190","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1210\/jc.2017-01996","article-title":"Purkinje cell protein 4 expression is associated with DNA methylation status in aldosterone-producing adenoma","volume":"103","author":"Kobuke","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2019041122013772000_B191","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1530\/EJE-15-0148","article-title":"Integration of transcriptome and methylome analysis of aldosterone-producing adenomas","volume":"173","author":"Murakami","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2019041122013772000_B192","doi-asserted-by":"crossref","first-page":"E536","DOI":"10.1210\/jc.2013-3495","article-title":"Integrated analysis of genome-wide methylation and gene expression shows epigenetic regulation of CYP11B2 in aldosteronomas","volume":"99","author":"Howard","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"1\u20132","key":"2019041122013772000_B193","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.mce.2013.11.022","article-title":"Development of monoclonal antibodies against human CYP11B1 and CYP11B2","volume":"383","author":"Gomez-Sanchez","year":"2014","journal-title":"Mol Cell Endocrinol"},{"issue":"4","key":"2019041122013772000_B194","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1161\/HYPERTENSIONAHA.115.05873","article-title":"Adrenal histopathology in primary aldosteronism: is it time for a change","volume":"66","author":"Gioco","year":"2015","journal-title":"Hypertension"},{"issue":"2","key":"2019041122013772000_B195","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1161\/HYPERTENSIONAHA.113.02944","article-title":"Different expression of 11\u03b2-hydroxylase and aldosterone synthase between aldosterone-producing microadenomas and macroadenomas","volume":"64","author":"Ono","year":"2014","journal-title":"Hypertension"},{"issue":"1\u20132","key":"2019041122013772000_B196","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.mce.2014.05.002","article-title":"Adrenal CYP11B1\/2 expression in primary aldosteronism: immunohistochemical analysis using novel monoclonal antibodies","volume":"392","author":"Nakamura","year":"2014","journal-title":"Mol Cell Endocrinol"},{"issue":"5","key":"2019041122013772000_B197","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1210\/jc.2009-2010","article-title":"Adrenocortical zonation in humans under normal and pathological conditions","volume":"95","author":"Nishimoto","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2019041122013772000_B198","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1161\/HYPERTENSIONAHA.110.158543","article-title":"Adrenal cortex remodeling and functional zona glomerulosa hyperplasia in primary aldosteronism","volume":"56","author":"Boulkroun","year":"2010","journal-title":"Hypertension"},{"issue":"33","key":"2019041122013772000_B199","doi-asserted-by":"crossref","first-page":"E4591","DOI":"10.1073\/pnas.1505529112","article-title":"Aldosterone-stimulating somatic gene mutations are common in normal adrenal glands","volume":"112","author":"Nishimoto","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"2019041122013772000_B200","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1210\/js.2017-00134","article-title":"Aldosterone-producing cell clusters frequently harbor somatic mutations and accumulate with age in normal adrenals","volume":"1","author":"Omata","year":"2017","journal-title":"J Endocr Soc"},{"issue":"12","key":"2019041122013772000_B201","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1055\/s-0043-122394","article-title":"Aldosterone-producing cell clusters in normal and pathological states","volume":"49","author":"Omata","year":"2017","journal-title":"Horm Metab Res"},{"issue":"3","key":"2019041122013772000_B202","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.tem.2016.01.003","article-title":"Local control of aldosterone production and primary aldosteronism","volume":"27","author":"Lalli","year":"2016","journal-title":"Trends Endocrinol Metab"},{"issue":"12","key":"2019041122013772000_B203","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1055\/s-0043-122238","article-title":"Disordered CYP11B2 expression in primary aldosteronism","volume":"49","author":"Gomez-Sanchez","year":"2017","journal-title":"Horm Metab Res"},{"issue":"1","key":"2019041122013772000_B204","doi-asserted-by":"crossref","first-page":"19546","DOI":"10.1038\/srep19546","article-title":"Activating mutations in CTNNB1 in aldosterone producing adenomas","volume":"6","author":"\u00c5kerstr\u00f6m","year":"2016","journal-title":"Sci Rep"},{"issue":"15","key":"2019041122013772000_B205","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMoa1504869","article-title":"Pregnancy, primary aldosteronism, and adrenal CTNNB1 mutations","volume":"373","author":"Teo","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"2019041122013772000_B206","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/cen.12873","article-title":"Novel somatic mutations in primary hyperaldosteronism are related to the clinical, radiological and pathological phenotype","volume":"83","author":"Scholl","year":"2015","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2019041122013772000_B207","doi-asserted-by":"crossref","first-page":"E419","DOI":"10.1210\/jc.2010-1885","article-title":"Wnt\/\u03b2-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: a study in cortisol-secreting and -nonsecreting tumors","volume":"96","author":"Bonnet","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2019041122013772000_B208","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1093\/hmg\/ddq029","article-title":"Constitutive \u03b2-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development","volume":"19","author":"Berthon","year":"2010","journal-title":"Hum Mol Genet"},{"issue":"17","key":"2019041122013772000_B209","doi-asserted-by":"crossref","first-page":"7622","DOI":"10.1158\/0008-5472.CAN-05-0593","article-title":"Mutations of \u03b2-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors","volume":"65","author":"Tissier","year":"2005","journal-title":"Cancer Res"},{"issue":"11","key":"2019041122013772000_B210","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1210\/en.2002-220275","article-title":"Wnt-4 deficiency alters mouse adrenal cortex function, reducing aldosterone production","volume":"143","author":"Heikkil\u00e4","year":"2002","journal-title":"Endocrinology"},{"issue":"1","key":"2019041122013772000_B211","doi-asserted-by":"crossref","first-page":"39121","DOI":"10.1038\/srep39121","article-title":"The prevalence of CTNNB1 mutations in primary aldosteronism and consequences for clinical outcomes","volume":"7","author":"Wu","year":"2017","journal-title":"Sci Rep"},{"issue":"6","key":"2019041122013772000_B212","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1210\/jc.2016-4007","article-title":"Genetic and histopathologic intertumor heterogeneity in primary aldosteronism","volume":"102","author":"Omata","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041122013772000_B213","doi-asserted-by":"crossref","first-page":"7834356","DOI":"10.1155\/2016\/7834356","article-title":"Human adrenocortical remodeling leading to aldosterone-producing cell cluster generation","volume":"2016","author":"Nishimoto","year":"2016","journal-title":"Int J Endocrinol"},{"issue":"2","key":"2019041122013772000_B214","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1161\/HYPERTENSIONAHA.117.10391","article-title":"Aging and adrenal aldosterone production","volume":"71","author":"Nanba","year":"2018","journal-title":"Hypertension"},{"issue":"5","key":"2019041122013772000_B215","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1681\/ASN.V651459","article-title":"Aldosterone responses to hyperkalemia in healthy elderly humans","volume":"6","author":"Mulkerrin","year":"1995","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"2019041122013772000_B216","first-page":"e13","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"issue":"3","key":"2019041122013772000_B217","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1161\/01.CIR.48.3.491","article-title":"Spironolactone as a nonspecific treatment for primary aldosteronism","volume":"48","author":"Bravo","year":"1973","journal-title":"Circulation"},{"issue":"5","key":"2019041122013772000_B218","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1291\/hypres.25.737","article-title":"Dietary sodium restriction restores nocturnal reduction of blood pressure in patients with primary aldosteronism","volume":"25","author":"Takakuwa","year":"2002","journal-title":"Hypertens Res"},{"issue":"3","key":"2019041122013772000_B219","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jamainternmed.2014.6278","article-title":"Dietary sodium content, mortality, and risk for cardiovascular events in older adults: the Health, Aging, and Body Composition (Health ABC) Study","volume":"175","author":"Kalogeropoulos","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"12","key":"2019041122013772000_B220","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1001\/jama.2018.1156","article-title":"Estimated 24-hour urinary sodium and potassium excretion in US adults","volume":"319","author":"Cogswell","year":"2018","journal-title":"JAMA"},{"issue":"5","key":"2019041122013772000_B221","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1161\/HYPERTENSIONAHA.108.111369","article-title":"Vascular remodeling and duration of hypertension predict outcome of adrenalectomy in primary aldosteronism patients","volume":"51","author":"Rossi","year":"2008","journal-title":"Hypertension"},{"issue":"5","key":"2019041122013772000_B222","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/HYPERTENSIONAHA.107.095448","article-title":"Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism","volume":"50","author":"Catena","year":"2007","journal-title":"Hypertension"},{"issue":"3","key":"2019041122013772000_B223","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/ajh\/hpu154","article-title":"Adrenalectomy is comparable with medical treatment for reduction of left ventricular mass in primary aldosteronism: meta-analysis of long-term studies","volume":"28","author":"Marzano","year":"2015","journal-title":"Am J Hypertens"},{"issue":"7","key":"2019041122013772000_B224","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1245\/s10434-013-2871-3","article-title":"Medical or surgical therapy for primary aldosteronism: post-treatment follow-up as a surrogate measure of comparative outcomes","volume":"20","author":"Kline","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"2019041122013772000_B225","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1530\/EJE-12-0631","article-title":"Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism","volume":"168","author":"Fourkiotis","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2019041122013772000_B226","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1210\/jc.2017-01442","article-title":"Quality of life in primary aldosteronism: a comparative effectiveness study of adrenalectomy and medical treatment","volume":"103","author":"Velema","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2019041122013772000_B227","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1055\/s-0043-121706","article-title":"Health-related quality of life and mental health in primary aldosteronism: a systematic review","volume":"49","author":"Velema","year":"2017","journal-title":"Horm Metab Res"},{"issue":"3","key":"2019041122013772000_B228","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1210\/jc.2009-1763","article-title":"Improved quality of life, blood pressure, and biochemical status following laparoscopic adrenalectomy for unilateral primary aldosteronism","volume":"95","author":"Sukor","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2019041122013772000_B229","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1001\/archsurg.1996.01430180072015","article-title":"Factors influencing outcome of surgery for primary aldosteronism","volume":"131","author":"Celen","year":"1996","journal-title":"Arch Surg"},{"issue":"2","key":"2019041122013772000_B230","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00268-004-7496-z","article-title":"Long-term follow-up after adrenalectomy for primary aldosteronism","volume":"29","author":"Meyer","year":"2005","journal-title":"World J Surg"},{"issue":"5","key":"2019041122013772000_B231","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0748-7983(03)00051-9","article-title":"Review of surgical management of aldosterone secreting tumours of the adrenal cortex","volume":"29","author":"Harris","year":"2003","journal-title":"Eur J Surg Oncol"},{"issue":"11","key":"2019041122013772000_B232","doi-asserted-by":"crossref","first-page":"877","DOI":"10.7326\/0003-4819-121-11-199412010-00010","article-title":"Diagnosis and treatment of primary hyperaldosteronism","volume":"121","author":"Blumenfeld","year":"1994","journal-title":"Ann Intern Med"},{"issue":"6","key":"2019041122013772000_B233","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1067\/msy.1998.93108","article-title":"Essential hypertension: first reason for persistent hypertension after unilateral adrenalectomy for primary aldosteronism","volume":"124","author":"Proye","year":"1998","journal-title":"Surgery"},{"issue":"2","key":"2019041122013772000_B234","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/00000658-199608000-00003","article-title":"Primary aldosteronism. Results of surgical treatment","volume":"224","author":"Lo","year":"1996","journal-title":"Ann Surg"},{"issue":"4","key":"2019041122013772000_B235","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1440-1681.1994.tb02520.x","article-title":"Response to unilateral adrenalectomy for aldosterone-producing adenoma: effect of potassium levels and angiotensin responsiveness","volume":"21","author":"Stowasser","year":"1994","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"2019041122013772000_B236","doi-asserted-by":"crossref","unstructured":"Hundemer GL , CurhanGC, YozampN, WangM, VaidyaA. Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism. JAMA Cardiol. 2018;3(8):768\u2013774.","DOI":"10.1001\/jamacardio.2018.2003"},{"issue":"1","key":"2019041122013772000_B237","doi-asserted-by":"crossref","first-page":"32103","DOI":"10.1038\/srep32103","article-title":"Long term outcome of aldosteronism after target treatments","volume":"6","author":"Wu","year":"2016","journal-title":"Sci Rep"},{"issue":"8","key":"2019041122013772000_B238","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1097\/HJH.0000000000001361","article-title":"Risk of new-onset diabetes mellitus in primary aldosteronism: a population study over 5 years","volume":"35","author":"Wu","year":"2017","journal-title":"J Hypertens"},{"issue":"4","key":"2019041122013772000_B239","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1161\/HYPERTENSIONAHA.118.10759","article-title":"Medical versus surgical treatment of primary aldosteronism","volume":"71","author":"Calhoun","year":"2018","journal-title":"Hypertension"},{"key":"2019041122013772000_B240","doi-asserted-by":"crossref","unstructured":"Hundemer GL , CurhanGC, YozampN, WangM, VaidyaA. Renal outcomes in medically and surgically treated primary aldosteronism. Hypertension. 2018;72(3):658\u2013666.","DOI":"10.1161\/HYPERTENSIONAHA.118.11568"},{"issue":"3","key":"2019041122013772000_B241","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/jch.12914","article-title":"Effects of treating primary aldosteronism on renal function","volume":"19","author":"Kramers","year":"2017","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"3","key":"2019041122013772000_B242","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00004872-200103000-00001","article-title":"A review of the medical treatment of primary aldosteronism","volume":"19","author":"Lim","year":"2001","journal-title":"J Hypertens"},{"issue":"9","key":"2019041122013772000_B243","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S2213-8587(17)30135-3","article-title":"Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort","volume":"5","author":"Williams","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2019041122013772000_B244","doi-asserted-by":"crossref","unstructured":"Williams TA , BurrelloJ, SechiLA, FardellaCE, MatrozovaJ, AdolfC, BaudrandR, BernardiS, BeuschleinF, CatenaC, DoumasM, FalloF, GiacchettiG, HeinrichDA, Saint-HilaryG, JansenPM, JanuszewiczA, KocjanT, NishikawaT, QuinklerM, SatohF, UmakoshiH, Widimsk\u00fdJJr, HahnerS, DoumaS, StowasserM, MulateroP, ReinckeM. Computed tomography and adrenal venous sampling in the diagnosis of unilateral primary aldosteronism. Hypertension. 2018;72(3):641\u2013649.","DOI":"10.1161\/HYPERTENSIONAHA.118.11382"},{"issue":"7","key":"2019041122013772000_B245","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1210\/jc.2006-2631","article-title":"Measurement of 18-hydroxycorticosterone during adrenal vein sampling for primary aldosteronism","volume":"92","author":"Auchus","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2019041122013772000_B246","doi-asserted-by":"crossref","first-page":"E1272","DOI":"10.1210\/jc.2010-2785","article-title":"18-Oxocortisol measurement in adrenal vein sampling as a biomarker for subclassifying primary aldosteronism","volume":"96","author":"Nakamura","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2019041122013772000_B247","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1161\/HYPERTENSIONAHA.114.04453","article-title":"Measurement of peripheral plasma 18-oxocortisol can discriminate unilateral adenoma from bilateral diseases in patients with primary aldosteronism","volume":"65","author":"Satoh","year":"2015","journal-title":"Hypertension"},{"key":"2019041122013772000_B248","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1097\/01.hjh.0000467656.46285.fb","article-title":"8d.02: Peripheral plasma 18-oxocortisol can discriminate unilateral adenoma from bilateral diseases in primary aldosteronism patients","volume":"33","author":"Satoh","year":"2015","journal-title":"J Hypertens"},{"issue":"1","key":"2019041122013772000_B249","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/ejhf.444","article-title":"Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease","volume":"18","author":"Bramlage","year":"2016","journal-title":"Eur J Heart Fail"}],"container-title":["Endocrine Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/edrv\/article-pdf\/39\/6\/1057\/26660673\/er.2018-00139.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T06:32:14Z","timestamp":1661754734000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/edrv\/article\/39\/6\/1057\/5074252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,15]]},"references-count":249,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,8,15]]},"published-print":{"date-parts":[[2018,12,1]]}},"URL":"https:\/\/doi.org\/10.1210\/er.2018-00139","relation":{},"ISSN":["0163-769X","1945-7189"],"issn-type":[{"value":"0163-769X","type":"print"},{"value":"1945-7189","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,12]]},"published":{"date-parts":[[2018,8,15]]}}}